Literature DB >> 33637679

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies.

Yang Yang1,2,3, Lanying Du4.   

Abstract

Entities:  

Year:  2021        PMID： 33637679      PMCID： PMC7908000          DOI： 10.1038/s41392-021-00523-5

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN： 2059-3635


× No keyword cloud information.
  5 in total

1.  Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.

Authors:  Eric Salazar; Suresh V Kuchipudi; Paul A Christensen; Todd Eagar; Xin Yi; Picheng Zhao; Zhicheng Jin; S Wesley Long; Randall J Olsen; Jian Chen; Brian Castillo; Christopher Leveque; Dalton Towers; Jason Lavinder; Jimmy Gollihar; Jose Cardona; Gregory Ippolito; Ruth Nissly; Ian Bird; Denver Greenawalt; Randall M Rossi; Abhinay Gontu; Sreenidhi Srinivasan; Indira Poojary; Isabella M Cattadori; Peter J Hudson; Nicole M Josleyn; Laura Prugar; Kathleen Huie; Andrew Herbert; David W Bernard; John M Dye; Vivek Kapur; James M Musser
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

2.  Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2.

Authors:  Shibo Jiang; Lanying Du
Journal:  Trends Immunol       Date:  2020-08-11       Impact factor: 16.687

3.  Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.

Authors:  Anita S Iyer; Forrest K Jones; Ariana Nodoushani; Jason B Harris; Richelle C Charles; Meagan Kelly; Margaret Becker; Damien Slater; Rachel Mills; Erica Teng; Mohammad Kamruzzaman; Wilfredo F Garcia-Beltran; Michael Astudillo; Diane Yang; Tyler E Miller; Elizabeth Oliver; Stephanie Fischinger; Caroline Atyeo; A John Iafrate; Stephen B Calderwood; Stephen A Lauer; Jingyou Yu; Zhenfeng Li; Jared Feldman; Blake M Hauser; Timothy M Caradonna; John A Branda; Sarah E Turbett; Regina C LaRocque; Guillaume Mellon; Dan H Barouch; Aaron G Schmidt; Andrew S Azman; Galit Alter; Edward T Ryan
Journal:  Sci Immunol       Date:  2020-10-08

Review 4.  Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.

Authors:  Ning Wang; Jian Shang; Shibo Jiang; Lanying Du
Journal:  Front Microbiol       Date:  2020-02-28       Impact factor: 5.640

5.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.

Authors:  Ania Wajnberg; Fatima Amanat; Adolfo Firpo; Deena R Altman; Mark J Bailey; Mayce Mansour; Meagan McMahon; Philip Meade; Damodara Rao Mendu; Kimberly Muellers; Daniel Stadlbauer; Kimberly Stone; Shirin Strohmeier; Viviana Simon; Judith Aberg; David L Reich; Florian Krammer; Carlos Cordon-Cardo
Journal:  Science       Date:  2020-10-28       Impact factor: 47.728
  5 in total
  30 in total

Review 1.  Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.

Authors:  Lanying Du; Yang Yang; Xiujuan Zhang; Fang Li
Journal:  Nanoscale       Date:  2022-01-27       Impact factor: 7.790

2.  [Change in serum IgG antibody during the recovery stage of Omicron variant infection in children: an analysis of 110 cases].

Authors:  Ping-Ping Zhang; Yan-Ting Guo; Yu-Qin Chu; Q I Ji; Yan Lian; Wei Li; Li-Na Yao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-07-15

3.  Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection.

Authors:  Rachel M Gittelman; Enrico Lavezzo; Thomas M Snyder; H Jabran Zahid; Cara L Carty; Rebecca Elyanow; Sudeb Dalai; Ilan Kirsch; Lance Baldo; Laura Manuto; Elisa Franchin; Claudia Del Vecchio; Monia Pacenti; Caterina Boldrin; Margherita Cattai; Francesca Saluzzo; Andrea Padoan; Mario Plebani; Fabio Simeoni; Jessica Bordini; Nicola I Lorè; Dejan Lazarević; Daniela M Cirillo; Paolo Ghia; Stefano Toppo; Jonathan M Carlson; Harlan S Robins; Andrea Crisanti; Giovanni Tonon
Journal:  JCI Insight       Date:  2022-05-23

Review 4.  Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination.

Authors:  Danilo Toni; Alexander E Merkler; Manuela De Michele; Joshua Kahan; Irene Berto; Oscar G Schiavo; Marta Iacobucci
Journal:  Circ Res       Date:  2022-04-14       Impact factor: 23.213

Review 5.  Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).

Authors:  Monic Andrew; Gurunathan Jayaraman
Journal:  Carbohydr Res       Date:  2021-05-03       Impact factor: 2.975

6.  Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.

Authors:  Yolanda Braun-Moscovici; Marielle Kaplan; Maya Braun; Doron Markovits; Samy Giryes; Kohava Toledano; Yonit Tavor; Katya Dolnikov; Alexandra Balbir-Gurman
Journal:  Ann Rheum Dis       Date:  2021-06-18       Impact factor: 19.103

7.  Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy.

Authors:  Immacolata Polvere; Alfredina Parrella; Giovanna Casamassa; Silvia D'Andrea; Annamaria Tizzano; Gaetano Cardinale; Serena Voccola; Piercarmine Porcaro; Romania Stilo; Pasquale Vito; Tiziana Zotti
Journal:  Diagnostics (Basel)       Date:  2021-03-09

8.  Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19.

Authors:  Sun Bean Kim; Jimin Kim; Kyungmin Huh; Won Suk Choi; Yae Jean Kim; Eun Jeong Joo; Youn Jeong Kim; Young Kyung Yoon; Jung Yeon Heo; Yu Bin Seo; Su Jin Jeong; Su Yeon Yu; Kyong Ran Peck; Miyoung Choi; Joon Sup Yeom
Journal:  Infect Chemother       Date:  2021-06

Review 9.  Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view.

Authors:  Ali Najmeddin; Mina Bahrololoumi Shapourabadi; Mahdi Behdani; Farid Dorkoosh
Journal:  Biochim Biophys Acta Gen Subj       Date:  2021-07-31       Impact factor: 3.770

Review 10.  SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies.

Authors:  Ahmed M Almehdi; Ghalia Khoder; Aminah S Alchakee; Azizeh T Alsayyid; Nadin H Sarg; Sameh S M Soliman
Journal:  Infection       Date:  2021-08-02       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.